Neurocrine Biosciences’ Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
3
0
Wednesday, Neurocrine Biosciences, Inc. (NASDAQ: NBIX) topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.
The new data showed that the once-daily 20 mg dose of NBI-‘568 induced an average 18.2-point reduction from baseline in the Positive and Negative Syndrome Scale (PANSS) after six weeks, compared to 10.8 points in the placebo group.
That 7.5-point difference reached statistical significance with a p-value of p=0.011.
The company noted that none of the other three higher-dosing groups (30, 40, and 60 mg) reached statistical significance.
Piper Sandler upgraded the stock from Neutral to …
Full story available on Benzinga.com
Visited 3 times, 1 visit(s) today